Avedro has resubmitted a new drug application for its riboflavin opthalmic solution/KXL system for corneal cross-linking (CXL).
Powered by Steuernachrichten
AAO News Archive
- Deal struck to develop integrin antagonist treatment
- New low-add multifocal IOLs yield higher patient satisfaction
- Regeneron, Bayer to develop AMD combination therapy
- FDA approves wide-field imaging system for newborns
- Brain mapping may someday lead to vision-restoring therapies
- FDA warns of loose safety seals on eye drops
- Stem cells regrow human lens, corneal tissue
Find an Eye MD near you!
Avedro resubmits FDA application for CXL treatment
- Details